COMPANY

Revel Pharmaceuticals

Location: San Francisco, CA · source · Mar 23, 2022

Profile checked Oct 10, 2026

Funding and NIH signals

NIH award NIH awarded $924K (SBIR Phase II 5R44AG084351-03, continuation, notice Jul 10, 2026). NIH RePORTER 5R44AG084351-03 (Jul 10, 2026)
Evidence (1 event)
- Jul 10, 2026 · NIH RePORTER 5R44AG084351-03
  Organization: REVEL PHARMACEUTICALS INC.; City/State: San Francisco, CA; Project number: 5R44AG084351-03; Activity code: R44; Fiscal year: 2026; Award notice date: 2026-07-10; FY total cost (award amount): 923550; Administering IC: National Institute on Aging; Project title: Development of enzymatic tools for rapid measurement of Advanced Glycation and Lipoxidation End Product-protein adducts; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Jul 10, 2026 Grant Government grant — SBIR: $923,550 (annual award, as published), announced Jul 10, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Aug 14, 2025 Grant Government grant — SBIR: $1.36M (annual award, as published), announced Aug 14, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Jul 25, 2025 Grant Government grant — SBIR: $358,065 (annual award, as published), announced Jul 25, 2025. Agency: NIH/NEI. Source: government award database. source ↗

Last 2 years.

Jul 10, 2026 Government grant — SBIR: $923,550 (annual award, as published), announced Jul 10, 2026. Agency: NIH/NIA. Source: government award database. source ↗
Aug 14, 2025 Government grant — SBIR: $1.36M (annual award, as published), announced Aug 14, 2025. Agency: NIH/NIA. Source: government award database. source ↗
Jul 25, 2025 Government grant — SBIR: $358,065 (annual award, as published), announced Jul 25, 2025. Agency: NIH/NEI. Source: government award database. source ↗